2024
Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status
Re V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology And Drug Safety 2024, 33: e70069. PMID: 39662972, PMCID: PMC11634562, DOI: 10.1002/pds.70069.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemical and Drug Induced Liver InjuryChronic DiseaseCohort StudiesFemaleHospitalizationHumansLiver DiseasesMaleMiddle AgedPharmacoepidemiologyProton Pump InhibitorsUnited StatesUnited States Department of Veterans AffairsConceptsProton pump inhibitor initiationHazard ratioVeterans Health AdministrationSevere acute liver injuryProton pump inhibitorsChronic liver diseaseAcute liver injuryRates of hospitalizationSafety of medicationsPPI initiativesHealth AdministrationLiver disease statusMedication exposurePharmacoepidemiological studiesMedicationConfoundingScoresReports of hepatotoxicityDisease statusHepatotoxic medicationsDrug exposurePump inhibitorsHepatotoxic drugsOutpatient initiationHepatic safety
2016
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. The American Journal Of Gastroenterology 2016, 112: 18. PMID: 27995906, DOI: 10.1038/ajg.2016.517.Peer-Reviewed Original ResearchMeSH KeywordsAlanine TransaminaseAlkaline PhosphataseAlpha 1-Antitrypsin DeficiencyAspartate AminotransferasesBilirubinBiopsyChemical and Drug Induced Liver InjuryCholestasisHemochromatosisHepatitis, AutoimmuneHepatitis, Viral, HumanHepatolenticular DegenerationHumansLiverLiver DiseasesLiver Diseases, AlcoholicNon-alcoholic Fatty Liver DiseaseConceptsAbnormal liver chemistriesLiver chemistriesAlkaline phosphatase levelsAlanine aminotransferaseHepatocellular diseaseAspartate aminotransferaseALT levelsDisproportionate elevationHepatocellular injuryLiver diseasePhosphatase levelsElevated total serum bilirubin (TSB) levelsIU/Conjugated bilirubinNonalcoholic fatty liver diseaseTotal serum bilirubin levelsAlpha-1 antitrypsin deficiencyElevated conjugated bilirubinSerum conjugated bilirubinTotal bilirubin elevationLiver-related mortalityElevated alanine aminotransferasePrimary sclerosing cholangitisViral hepatitis AAlcoholic liver diseaseHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchMeSH KeywordsAlanine TransaminaseAspartate AminotransferasesBuprenorphineChemical and Drug Induced Liver InjuryCohort StudiesCoinfectionFemaleHepatitis CHIV InfectionsHumansMaleMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersRisk FactorsConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection